Charcot-Marie-Tooth disease type 1E: clinical natural history and molecular impact of <i>PMP22</i> variants

Charcot-Marie-Tooth disease type 1E (CMT1E) is a rare, autosomal dominant peripheral neuropathy caused by missense variants, deletions, and truncations within the peripheral myelin protein-22 (PMP22) gene. CMT1E phenotypes vary depending on the specific variant, ranging from mild to severe, and there is little natural history and phenotypic progression data on individuals with CMT1E. Patients with CMT1E were evaluated during initial and follow-up visits at sites within the Inherited Neuropathy Consortium. Clinical characteristics were obtained from history, neurological exams, and nerve conduction studies. Clinical outcome measures were used to quantify baseline and longitudinal changes, including the Rasch-modified CMT Examination Score version 2 (CMTESv2-R) and the CMT Pediatric Scale (CMTPedS). The trafficking of PMP22 variants in transfected cells was correlated to disease severity. Twenty-four presumed disease-causing PMP22 variants were identified in 50 individuals from 35 families, including 19 missense variants, three in-frame deletions, and two truncations. Twenty-nine patients presented with delayed walking during childhood. At their baseline evaluation, the mean CMTESv2-R in 46 patients was 16 ± 7.72 (out of 32), and the mean CMTPedS from 17 patients was 28 ± 6.35 (out of 44). Six individuals presented with hearing loss, eleven with scoliosis, three with hip dysplasia, and one with both scoliosis and hip dysplasia. Twenty variants were localized within transmembrane domains; 31 of 35 individuals with these variants had moderate to severe phenotypes. Three variants were found in the extracellular domain and were associated with milder phenotypes. Reduced expression of PMP22 at the cell surface, and the location of missense variants within the transmembrane domain correlated with disease severity. Pathogenic PMP22 variants located within the transmembrane regions usually cause a moderate to severe clinical phenotype, beginning in early childhood, and have impaired trafficking to the plasma membrane.

Authors

Institutions

Publication Details

Journal
Brain
Published
2025-06-06
DOI
https://doi.org/10.1093/brain/awaf219
Citations
1
Primary Topic
Hereditary Neurological Disorders
Type
article
Field-Weighted Citation Impact
0.91
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Charcot-Marie-Tooth disease type 1E: clinical natural history and molecular impact of PMP22 variants

Alexander Martin Rossor, Gita Ramdharry, Robert C. Piper, Richard A. Lewis et al.
1 citations
Brain
Hereditary Neurological Disorders
0.91
article

Charcot-Marie-Tooth disease type 1E: clinical natural history and molecular impact of PMP22 variants

Alexander Martin Rossor, Gita Ramdharry, Robert C. Piper, Richard A. Lewis, Andrea Cortese, Steven S. Scherer, Diana Xerxes Bharucha-Goebel, Chiara Pisciotta, Amedeo De Grado, Mary M. Reilly, Tim Estilow, Christopher P. Ptak, Tiffany Grider, Sabrina W. Yum, John Svaren, Michael E. Shy, Mario Saporta, Daniele Cazzato, Stephan Züchner, Kayla Cornett, Tara Jones, M I Greene, Paola Saveri, Reza Sadjadi, Kevin R. Ward, Davide Pareyson, David Walk, Tabitha A. Peterson, Natalya Pashkova, Gyula Acsádi, Brett A. McCray, Carsten G. Bönnemann, Francesco Muntoni, Seth J. Perlman, Vera Fridman, Eleonora Cavalca, Paola Lanteri, Isabella Moroni, Manoj P. Menezes, Omer Abdul Hamid, Kate Eichinger, Rebecca Traub, Richard S. Finkel, Charlotte J. Sumner, Franco Taroni, Luca Crivellari, Bipasha Mukherjee‐Clavin, Jun Li, David N. Herrmann, Matilde Laurà, Joshua Burns, Hernan Gonorazki
article en
1 citations

Abstract

Charcot-Marie-Tooth disease type 1E (CMT1E) is a rare, autosomal dominant peripheral neuropathy caused by missense variants, deletions, and truncations within the peripheral myelin protein-22 (PMP22) gene. CMT1E phenotypes vary depending on the specific variant, ranging from mild to severe, and there is little natural history and phenotypic progression data on individuals with CMT1E. Patients with CMT1E were evaluated during initial and follow-up visits at sites within the Inherited Neuropathy Consortium. Clinical characteristics were obtained from history, neurological exams, and nerve conduction studies. Clinical outcome measures were used to quantify baseline and longitudinal changes, including the Rasch-modified CMT Examination Score version 2 (CMTESv2-R) and the CMT Pediatric Scale (CMTPedS). The trafficking of PMP22 variants in transfected cells was correlated to disease severity. Twenty-four presumed disease-causing PMP22 variants were identified in 50 individuals from 35 families, including 19 missense variants, three in-frame deletions, and two truncations. Twenty-nine patients presented with delayed walking during childhood. At their baseline evaluation, the mean CMTESv2-R in 46 patients was 16 ± 7.72 (out of 32), and the mean CMTPedS from 17 patients was 28 ± 6.35 (out of 44). Six individuals presented with hearing loss, eleven with scoliosis, three with hip dysplasia, and one with both scoliosis and hip dysplasia. Twenty variants were localized within transmembrane domains; 31 of 35 individuals with these variants had moderate to severe phenotypes. Three variants were found in the extracellular domain and were associated with milder phenotypes. Reduced expression of PMP22 at the cell surface, and the location of missense variants within the transmembrane domain correlated with disease severity. Pathogenic PMP22 variants located within the transmembrane regions usually cause a moderate to severe clinical phenotype, beginning in early childhood, and have impaired trafficking to the plasma membrane.

BrainVol. 149(3)
University of Iowa (US), The University of Sydney (AU), University of Minnesota (US), St. Jude Children's Research Hospital (US), Johns Hopkins University (US), University of Miami (US), Johns Hopkins Medicine (US), Massachusetts General Hospital (US), Sydney Children's Hospital (AU), Dr. John T. Macdonald Foundation (US), University of Iowa Health Care (US), Sydney Children’s Hospitals Network (AU), National Hospital for Neurology and Neurosurgery (GB), Fondazione IRCCS Istituto Neurologico Carlo Besta (IT), University College London (GB), University of Rochester (US), University of Pennsylvania (US), Stanford University (US)
Good health and well-being
Openalex Percentile: Top 26%
Hereditary Neurological Disorders
0.91
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.